

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

Location: Zoom  
Meeting ID: 303 413 3898  
Password: 8625

**IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS**

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO “ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE” 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT [aragadio@alamedaalliance.org](mailto:aragadio@alamedaalliance.org) . YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK <https://amerihealthcaritas.zoom.us> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-669-900-6833. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

**PLEASE NOTE:** THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

## AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>Conflict of Interest Check/Disclosure</li> <li>Agenda Overview</li> </ul>	2 min	-
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>COVID-19 Update</li> <li>Pharmacy Carve Out Update</li> <li>CalAim Update</li> <li>LTC Update</li> <li>NCQA Survey Update</li> </ul>	15 min	-

**III) Pharmacy Utilization Reports (Quarter 1)**

*Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance*

- Top 50 Drugs by Cost
- Top 100 PA Reviewed Drugs

**IV) E-Voting Material/Consent Agenda**

**The following items have been sent to the voting committee for review via E-voting**

*Natalee Felten, PharmD, Pharmacist, PerformRx*

*(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)*

Monographs/Class Reviews	Changes
Contraceptive foams devices Class Review	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Sucraid Monograph	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Ridaura Monograph	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Medication Request Guidelines	Changes
Formulary, step therapy required *For drugs without specific criteria	<ul style="list-style-type: none"> <li>• Remove extraneous word “limit”</li> </ul>
Angiotensin II Receptor Blockers and Renin Inhibitors	<ul style="list-style-type: none"> <li>• Update drug ingredients for Edarbyclor</li> <li>• Update brand/generic status of Tekturna</li> <li>• Update generic Tribenzor strengths</li> <li>• Add CCS statement</li> </ul>
Corlanor (ivabradine)	<ul style="list-style-type: none"> <li>• Add “a” missing in prescriber restrictions</li> <li>• Change order of wording of 6th bullet</li> <li>• Move 6th bullet point up and move 3 sub-bullets to the left</li> <li>• Add CCS statement</li> </ul>
Fenofibrates	<ul style="list-style-type: none"> <li>• Add 2 NF formulations of fenofibrate</li> </ul>
Tiagabine (Gabitril)	<ul style="list-style-type: none"> <li>• Add clarifying word of “one”</li> </ul>
Ophthalmic Anti-inflammatory Immunomodulators	<ul style="list-style-type: none"> <li>• Correct spelling of “previously”</li> </ul>
Specialty Biological Agents for Hidradenitis Suppurativa	<ul style="list-style-type: none"> <li>• Add statement “Or any newly marketed agent”</li> <li>• Spelling corrections in criteria and criteria statement</li> </ul>
Specialty Biological Agents for Giant Cell Arteritis	<ul style="list-style-type: none"> <li>• Add statement “Or any newly marketed agent”</li> </ul>
Specialty Biological Agents for Uveitis	<ul style="list-style-type: none"> <li>• Add statement “Or any newly marketed agent”</li> </ul>
Epidiolex (cannabidiol)	<ul style="list-style-type: none"> <li>• Add CCS statement</li> </ul>
Non-formulary and prior authorization required oral liquid formulations	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Carbamazepine	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Cholinesterase Inhibitors	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Daliresp (roflumilast)	<ul style="list-style-type: none"> <li>• No changes</li> </ul>
Vimpat (lacosamide)	<ul style="list-style-type: none"> <li>• No changes</li> </ul>

10 min

**EV**  
*(on each topic)*

Lamotrigine ER	• No changes
Levalbuterol (Xopenex/Xopenex HFA)	• No changes
Nutritional formulas, infant formulas (STC)	• No changes
Banzel (rufinamide)	• No changes
<b>Interim Formulary changes</b>	
• See p. 55 in packet	
<b>Pharmacy Policies &amp; Procedures Updates</b>	
Policy & Procedure RX-003	Up to 30 day supply override after discharge
Policy & Procedure RX-010	Additional updates to opioid DUR program per APL 19-02
<b>P&amp;T Meeting Minutes</b>	
P&T Meeting Minutes Q1 March 17, 2020	

**ADJOURN TO CLOSED SESSION** (Pursuant to California Government Code Title 5, §54954.5(h))

**Discussion will Concern:** Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes  
**Estimated Date of Public Disclosure:** 06/16/2020 (formulary changes only; no trade secrets will be disclosed).

**V) New Business**

Natalee Felten, PharmD, Pharmacist, PerformRx

Timothy Tong, PharmD, Pharmacist, Alameda Alliance

- Rectiv Medication Request Guideline
- Physician Administered Drug (PAD) Medication Request Guideline Document

**VI) Class Reviews, Monographs, and Recommendations**

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Non-opioid pain management (neuropathic pain) Class Review
2. CGRPs Class Review
3. Reyvow monograph
4. Narcolepsy Class Review
5. Gout Class Review
6. Palforzia Monograph
7. Adakveo Monograph

60 min **V**  
(on each topic)

**RECONVENE IN OPEN SESSION**

ITEM	DESCRIPTION	TIME	VOTE
<b>VII)</b>	<b>Summary of Closed Session</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	2min	-
<b>VIII)</b>	<b>Medication Request Guidelines</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>		
	<ol style="list-style-type: none"> <li>1. Alprazolam (Xanax)</li> <li>2. Hepatitis C Medications</li> <li>3. Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations</li> <li>4. Potassium-removing agents</li> <li>5. Serotonin Receptor Agonists (Triptans)</li> <li>6. Emflaza (deflazacort)</li> <li>7. Specialty Biological Agents for Crohn’s Disease</li> </ol>	10 min	<b>V</b>

8. Specialty Biological Agents for Ulcerative Colitis
9. Specialty Biological Agents for Rheumatoid Arthritis
10. Specialty Biological Agents for Psoriatic Arthritis (PsA)
11. Specialty Biological Agents for Psoriasis
12. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis
13. Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis
14. Specialty Biological Agents for Non-FDA Approved Medically Accepted Indications
15. Movement Disorders
16. PCSK-9 Inhibitors
17. Hemlibra (emicizumab-kxwh)
18. Brand Medications When Generic is Available
19. Rapid-Acting Insulin
20. Long-Acting Basal Insulin
21. vigabatrin (Sabril)
22. dalfampridine (Ampyra)
23. Central Nervous System Stimulants
24. Oral and Injectable Oncology Medications

<b>IX) Informational Updates on New Developments in Pharmacy</b>			
<i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>		2 min	-
• New Product Review			
<b>X) Old Business</b>		0 min	
• None			
<b>XI) Public Comment</b>		0 min	-
<b>XII) Adjournment</b>			
• P&T Committee Member Forms		-	-

<b>ACTION / FOLLOW-UP ITEMS</b>		
<b>ITEM</b>	<b>DUE DATE</b>	<b>RESPONSIBLE</b>

UPCOMING P&T MEETINGS	
NEXT MEETING	
September 15th, 2020	September 15 <sup>th</sup> , 2020
	December 15 <sup>th</sup> , 2020
	March 16 <sup>th</sup> , 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.

**Americans with Disabilities Act (ADA):** It is the intention of the Alameda Alliance for Health to comply with the Americans with Disabilities Act (ADA) in all respects. If, as an attendee or a participant at this meeting, you will need special assistance beyond what is normally provided, the Alameda Alliance for Health will attempt to accommodate you in every reasonable manner. Please contact Ashley Ragadio at [Aragadio@alamedaalliance.org](mailto:Aragadio@alamedaalliance.org) at least 48 hours prior to the meeting to inform us of your needs and to determine if accommodation is feasible. Please advise us at that time if you will need accommodations to attend or participate in meetings on a regular basis.